In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
News|Podcasts|February 16, 2026
ACT Brief: eSource Moves Toward AI-Enabled Validation, Outsourcing Models Shift Toward Flexibility, and Robust Trial Design Becomes Mission Critical
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we explore how eSource adoption is advancing with AI-enabled validation and interoperability, examine how flexible outsourcing models are helping sponsors balance control and efficiency, and highlight why adaptive, simulation-driven trial design is becoming essential to improving study success.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- A new ACT
FAQ outlines how EHR-to-EDC integrations are reducing manual transcription and improving data accuracy, while artificial intelligence is increasingly used to support quality checks and monitoring under human oversight. However, long-term scalability will depend on validation frameworks, regulatory alignment, and collaboration across sponsors, sites, and vendors to ensure AI-enabled workflows can be trusted and adopted at scale. - A new ACT contributor
article highlights growing adoption of the functional-service provider model, which allows sponsors to retain strategic oversight while leveraging CRO expertise to improve efficiency and resource allocation. Success depends on treating CROs as strategic partners, with strong communication and shared planning helping organizations transition without disrupting study timelines or quality standards. - Finally, a new industry
perspective emphasizes how adaptive trial designs and simulation-based planning allow sponsors to build flexibility into protocols and respond to real-world variability. By anticipating uncertainty early and adjusting designs as data emerges, sponsors can protect statistical integrity and improve the likelihood of achieving primary endpoints when outcomes matter most.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
Trending on Applied Clinical Trials Online
1
FDA Launches Rare Disease Framework Initiative to Reimagine Drug Development for Small Patient Populations
2
ACT Brief: Design Drivers of Trial Representation, eSource-to-EDC Data Automation, and Roche's ALK7 Obesity License
3
Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection
4
The Biggest Remaining Barriers to High-Quality RWE Across Oncology Data Platforms
5